Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phosphatidylinositol glycan anchor biosynthesis class U protein (PIGU) is a transmembrane enzyme and an essential component of the glycosylphosphatidylinositol-anchor (GPI-anchor) transamidase complex, mediating the post-translational attachment of GPI anchors to proteins in the endoplasmic reticulum[1][2][3][7]. PIGU helps recognize or bind the lipid portion of the GPI-anchor and organizes other subunits within the membrane, which is crucial for GPI-anchored protein biosynthesis. Mutations in PIGU can lead to neurodevelopmental disorders, and its overexpression has been linked to cancer progression through immune evasion and increased NF-κB pathway activation[3][5][6][7].
Catalytic subunit of GPI transamidase complex, facilitating GPI-anchor attachment to newly synthesized proteins in the endoplasmic reticulum
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol glycan anchor biosynthesis class U protein (PIGU).